IJERPH, Vol. 19, Pages 13949: Pharmacological Treatment of Arterial Hypertension in Children and Adolescents in Lithuania
enė The global prevalence of arterial hypertension (AH) in the pediatric population is increasing, but therapeutic approaches and the choice of the most suitable antihypertensive medications remains challenging. The study aimed to estimate the prevalence, treatment rates, and pharmacological treatment patterns of children and adolescents with AH in Lithuania during 2019 using real-world data. The study population consisted of citizens of Lithuania aged 0 to 17 years, who were diagnosed with AH according to the International Classification of Diseases (ICD). The analysis of reimbursed antihypertensive medication prescr...
Source: International Journal of Environmental Research and Public Health - October 27, 2022 Category: Environmental Health Authors: Eleonora Ivanova Dovil ė Ruzgienė Karolis A žukaitis Augustina Jankauskien ė Tags: Article Source Type: research

Cost-effectiveness of folic acid therapy for primary prevention of stroke in patients with hypertension
For hypertensive patients without a history of stroke or myocardial infarction (MI), the China Stroke Primary Prevention Trial (CSPPT) demonstrated that treatment with enalapril-folic acid reduced the risk of ... (Source: BMC Medicine)
Source: BMC Medicine - October 25, 2022 Category: Internal Medicine Authors: Tiantian Zhang, Zhuoru Liang, Tengfei Lin, David J. Cohen, Alejandro Arrieta, Xiaobin Wang, Xianhui Qin, Binyan Wang, Yong Huo, Gordon G. Liu, Jie Jiang and Zugui Zhang Tags: Research article Source Type: research

Robust arm and leg muscle adaptation to training despite ACE inhibition: a randomized placebo-controlled trial
ConclusionEight weeks of high-intensity whole-body exercise training improves markers of skeletal muscle mitochondrial oxidative capacity, glycolytic capacity and angiogenesis, with no overall effect of pharmacological ACE inhibition in healthy adults. (Source: European Journal of Applied Physiology)
Source: European Journal of Applied Physiology - October 22, 2022 Category: Physiology Source Type: research

Acute kidney injury and long-term renal effects of alectinib in anaplastic lymphoma kinase-positive non-small cell lung carcinoma: a case report
ConclusionsOur data suggest direct or indirect toxic (proximal) tubulopathy due to alectinib with a good prognosis after cessation. Adverse acute renal effects of alectinib may be prevented by avoiding other medication influencing renal hemodynamics, in particular nonsteroidal anti-inflammatory drugs. Without these co-medications, alectinib could be reintroduced in our patient. (Source: Journal of Medical Case Reports)
Source: Journal of Medical Case Reports - September 29, 2022 Category: General Medicine Source Type: research

The Relationship between Angiotensin-Neprilysin Treatment, Echocardiographic Parameters, and NT-proBNP Levels in HFpEF Patients with Acute Decompensated Heart Failure
CONCLUSION: Sacubitril-valsartan treatment, which lowered NT-proBNP levels and improved cardiac function, was more effective in HFpEF patients with acute decompensated heart failure than enalapril.PMID:36132549 | PMC:PMC9484936 | DOI:10.1155/2022/4298644 (Source: Computational and Mathematical Methods in Medicine)
Source: Computational and Mathematical Methods in Medicine - September 22, 2022 Category: Statistics Authors: Xiaoliang Zhang Song Yang Zhonglin Xu Source Type: research

Heart Failure Duration and Mechanistic Efficacy of Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction
Modulation of the renin-angiotensin system is one of the cornerstones for treatment of heart failure with reduced ejection fraction (HFrEF) (1). In the Prospective Comparison of Angiotensin Receptor –Neprilysin Inhibitor (ARNI) with Angiotensin Converting Enzyme (ACE) Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF) (2), treatment with the angiotensin receptor/neprilysin inhibitor (ARNI) sacubitril/valsartan (Sac/Val) significantly reduced c ardiovascular (CV) mortality and HF hospitalization compared to the ACE inhibitor enalapril; treatment with Sac/Val also reduced c...
Source: Journal of Cardiac Failure - September 16, 2022 Category: Cardiology Authors: Reza Mohebi, Yuxi Liu, G. Michael Felker, Margaret F. Prescott, Jonathan H. Ward, Ileana L. Pi ña, Javed Butler, Scott D. Solomon, James L. Januzzi Source Type: research

Intravital imaging of hemodynamic glomerular effects of enalapril or/and empagliflozin in STZ-diabetic mice
Conclusion: SGLT2 inhibition, besides ACE inhibition, is an essential hemodynamic regulator of glomerular filtration during diabetes mellitus. Nevertheless, additional mechanisms—independent from hemodynamic regulation—are involved in the nephroprotective effects especially of the combination therapy and should be further explored in future studies. (Source: Frontiers in Physiology)
Source: Frontiers in Physiology - September 12, 2022 Category: Physiology Source Type: research